Related Experiment Video
Updated: Jan 26, 2026

Investigating Migraine-Like Behavior Using Light Aversion in Mice
Published on: August 11, 2021
Therapeutic novelties in migraine: new drugs, new hope?
Thien Phu Do1, Song Guo1, Messoud Ashina2
1Danish Headache Center and Department of Neurology, Rigshospitalet Glostrup, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.
Background:
In the past decade, migraine research has identified novel drug targets. In this review, we discuss recent data on emerging anti-migraine therapies.
Main Body:
The development of ditans, gepants and anti-calcitonin gene-related peptide monoclonal antibodies for the treatment of migraine is one of the greatest advances in the migraine field. Lasmiditan, rimegepant and ubrogepant will extend our therapeutic armamentarium for managing acute migraine attacks when triptans are not effective or contraindicated due to cardiovascular disorders. The monoclonal antibodies are migraine specific prophylactic drugs with high responder rates and favorable adverse event profiles. Furthermore, they offer convenient treatment regimens of 4- or 12-week intervals.
Conclusion:
Collectively, novel migraine therapies represent a major progress in migraine treatment and will undoubtedly transform headache medicine.
Related Concept Videos
Antipsychotic Drugs: Therapeutic Uses and Side Effects
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Therapeutic Drug Monitoring: Drug Analysis Methods
Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring: Overview and Classification
Cardiovascular Drugs: Classification based on Therapeutic Indications
Therapeutic Index

